These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 21540399)

  • 1. Toxoplasmic encephalitis in an AIDS cohort at Puerto Rico before and after highly active antiretroviral therapy (HAART).
    Mayor AM; Fernández Santos DM; Dworkin MS; Ríos-Olivares E; Hunter-Mellado RF
    Am J Trop Med Hyg; 2011 May; 84(5):838-41. PubMed ID: 21540399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy.
    Antinori A; Larussa D; Cingolani A; Lorenzini P; Bossolasco S; Finazzi MG; Bongiovanni M; Guaraldi G; Grisetti S; Vigo B; Gigli B; Mariano A; Dalle Nogare ER; De Marco M; Moretti F; Corsi P; Abrescia N; Rellecati P; Castagna A; Mussini C; Ammassari A; Cinque P; d'Arminio Monforte A;
    Clin Infect Dis; 2004 Dec; 39(11):1681-91. PubMed ID: 15578371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the AIDS epidemiologic situation in Puerto Rico following health care reform and the introduction of HAART.
    Báez-Feliciano DV; Thomas JC; Gómez MA; Miranda S; Fernández DM; Velázquez M; Ríos-Olivares E; Hunter-Mellado RF
    Rev Panam Salud Publica; 2005 Feb; 17(2):92-101. PubMed ID: 15826386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis.
    Connolly MP; Goodwin E; Schey C; Zummo J
    Pathog Glob Health; 2017 Feb; 111(1):31-44. PubMed ID: 28090819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART).
    Kiderlen TR; Liesenfeld O; Schürmann D; Schneider T
    Eur J Clin Microbiol Infect Dis; 2011 Dec; 30(12):1521-5. PubMed ID: 21491176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ocular involvement in AIDS patients with central nervous system toxoplasmosis: before and after HAART].
    Zajdenweber M; Muccioli C; Belfort R
    Arq Bras Oftalmol; 2005; 68(6):773-5. PubMed ID: 17344978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Value and Safety of Stereotactic Biopsy in Acquired Immune Deficiency Syndrome Patients with Intracranial Lesions: Systematic Review and Meta-Analysis.
    Zhang J; Liu X; Fu K; Xu C; Gong R; Liu L; Guo T; Zhou H; Zhao X; Chen J; Zhang J
    World Neurosurg; 2017 Feb; 98():790-799.e13. PubMed ID: 27965075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses.
    Hoffmann C; Ernst M; Meyer P; Wolf E; Rosenkranz T; Plettenberg A; Stoehr A; Horst HA; Marienfeld K; Lange C
    Clin Microbiol Infect; 2007 May; 13(5):510-5. PubMed ID: 17298486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical analysis of 16 AIDS patients complicated with toxoplasmic encephalitis].
    Zhao JR; Zhang S; Du JP; Wang S; Wang DY
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2010 Jun; 28(3):237-8. PubMed ID: 20806515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings).
    Dedicoat M; Livesley N
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005420. PubMed ID: 16856096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era.
    Abgrall S; Rabaud C; Costagliola D;
    Clin Infect Dis; 2001 Nov; 33(10):1747-55. PubMed ID: 11595976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
    Ives NJ; Gazzard BG; Easterbrook PJ
    J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection.
    Schürmann D; Bergmann F; Albrecht H; Padberg J; Wünsche T; Grünewald T; Schürmann M; Grobusch M; Vallée M; Ruf B; Suttorp N
    Eur J Clin Microbiol Infect Dis; 2002 May; 21(5):353-61. PubMed ID: 12072919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epidemiologic characteristics of cerebral toxoplasmosis in 399 HIV-infected patients followed between 1983 and 1994].
    Bossi P; Caumes E; Astagneau P; Li TS; Paris L; Mengual X; Katlama C; Bricaire F
    Rev Med Interne; 1998 May; 19(5):313-7. PubMed ID: 9775164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of secondary prophylaxis against disseminated Mycobacterium avium complex infection and toxoplasmic encephalitis.
    Zeller V; Truffot C; Agher R; Bossi P; Tubiana R; Caumes E; Jouan M; Bricaire F; Katlama C
    Clin Infect Dis; 2002 Mar; 34(5):662-7. PubMed ID: 11810599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease.
    Murphy EL; Collier AC; Kalish LA; Assmann SF; Para MF; Flanigan TP; Kumar PN; Mintz L; Wallach FR; Nemo GJ;
    Ann Intern Med; 2001 Jul; 135(1):17-26. PubMed ID: 11434728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of highly active antiretroviral therapy (HAART) on the incidence of opportunistic infections, hospitalizations and mortality among children and adolescents living with HIV/AIDS in Belo Horizonte, Minas Gerais State, Brazil.
    Candiani TM; Pinto J; Cardoso CA; Carvalho IR; Dias AC; Carneiro M; Goulart EA
    Cad Saude Publica; 2007; 23 Suppl 3():S414-23. PubMed ID: 17992347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrimethamine as primary prophylaxis of toxoplasmic encephalitis in patients infected with human immunodeficiency virus: open study.
    Bachmeyer C; Gorin I; Deleuze J; Morini JP; Escande JP
    Clin Infect Dis; 1994 Mar; 18(3):479-80. PubMed ID: 8011845
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.